- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01791075
Comparing Endoglide to Endoserter for DSAEK Graft Insertion
Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With the Endoserter for Insertion of the Donor Graft in Descemets Stripping Endothelial Keratoplasty (DSAEK)
Study Overview
Status
Intervention / Treatment
Detailed Description
Descemet's stripping automated endothelial keratoplasty (DSAEK) is a widely performed method of corneal transplantation. It is now considered the standard of care for the treatment of endothelial cell dysfunction. The advantages of this technique include faster visual rehabilitation, decreased risk of allograft rejection, preservation of corneal tectonic strength, stable refraction, reduced irregular astigmatism, and less suture complications.
The standard of care at the Toronto Western Hospital for Dr. Rootman's and Dr. Slomovic's patients with corneal endothelial disease is to perform DSAEK surgery with the Tan Endoglide for insertion of the donor graft. Other surgeons at Toronto Western Hospital use either Busin glide or specifically designed forceps for insertion of the donor graft as part of the standard of care. Still others have advocated the use of the suture pull-through technique.
There is significant disagreement in the literature regarding the DSAEK insertion technique that best preserves the donor endothelium. Some investigators report better results with a forceps or sutures, and others caution against any folding. The less traumatic the insertion to the endothelium, the better the long term survival of the corneal transplant. In addition, surgeons also debate whether large- or small-incision DSAEK is better for the graft's long-term viability, its propensity for postoperative dislocation, and the ease of insertion in the OR. The proposed advantages of the Tan EndoGlide include consistent and reliable delivery of the corneal donor through a small incision with minimal endothelial loss. The advantages of a small-incision DSAEK are, that it provides a more stable wound postoperatively, sutureless surgery, speed, and convenience for combining the procedure with standard phacoemulsification. Balancing the attractiveness of small-incision DSAEK with the concern for endothelial injury from donor folding and forceps compression, the Endosaver (Ocular Systems, Inc., Winston-Salem, NC) a novel DSAEK injector device, has been recently introduced. It allows the surgeon to insert unfolded tissue without a forceps through a 4-mm clear corneal incision.
Both devices have been approved for use by Health Canada as a Class 1 device (http://www.angioedupro.com/Sharpoint/index.php?seek=394).
Recently, the results of a randomised prospective study being conducted by Dr. D. Tan (inventor of the Tan EndoGlide) were published. In this study the effect on endothelial cell counts using the Tan EndoGlide has been evaluated. The investigators report a 15.6% of endothelial cell loss 12 months after DSAEK surgery. There are no published studies regarding the Endosaver injector, nevertheless, preliminary results indicate poorer outcome (30% cell loss after one month). No study comparing the two devices in regard to endothelial cell loss was reported so far.
The purpose of this study is to compare the Tan EndoGlide with the new Endosaver injector in terms of damage to the donor corneal endothelium by comparing the endothelial cell loss at 1 month, 3 months, 6 months, and 1 year postoperatively. Our study would involve prospectively examining a total of 42 subjects (21 eyes with the Tan EndoGlide and 21 eyes with the Endosaver injector) and compare endothelial cell loss and visual outcomes between groups.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Uri Elbaz, MD
- Phone Number: 4163175662
- Email: urielbaz@gmail.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Recruiting
- Toronto Western Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients presenting with corneal decompensation requiring DSAEK with or without cataract surgery for visual rehabilitation.
- Clinical diagnosis include endothelial cell dysfunction secondary to Fuchs endothelial dystrophy, pseudophakic or aphakic bullous keratopathy, failed penetrating keratoplasty or DSAEK, iridocorneal endothelial syndrome or trauma.
- Ability to understand the nature of the procedure and give full informed consent.
- Patients who are able to comply with the standard DSAEK follow-up protocol at the Toronto Western Hospital.
Exclusion Criteria:
- Patients with late stage corneal decompensation with stromal scarring unsuitable for DSAEK and therefore requiring penetrating keratoplasty.
- Patients with complex anterior segment pathology precluding successful DSAEK procedure.
- Patients not giving full informed consent to participate in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tan Endoglide
Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
|
Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
|
Active Comparator: Endosaver/serter
Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
|
Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial cell count after 6 months and 12 months
Time Frame: 6,12 months post op
|
The patients will be evaluated for endothelial cell loss 6 and 12 post surgery
|
6,12 months post op
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity
Time Frame: 1 month and 3,6,12 months post surgery
|
The patients will be evaluated for Visual acuity stability/improvement at the previous mentioned intervals.
|
1 month and 3,6,12 months post surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: David S. Rootman, MD, TWH - UHN
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB 10-0631-B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fuch's Endothelial Dystrophy
-
University Hospital, RouenCompleted
-
Klinikum Chemnitz gGmbHGerman Research Foundation; KKS NetzwerkUnknownPseudophakic Bullous Keratopathy | Fuch's Endothelial DystrophyGermany
-
NYU Langone HealthNational Eye Institute (NEI)Active, not recruitingFuch's Dystrophy | Corneal Disorders | Prior SurgeryUnited States
-
Queen's UniversityWithdrawnCataracts | Fuch's Endothelial DystrophyCanada
-
National Eye Institute (NEI)Bausch & Lomb Incorporated; Eye Bank Association of America; Midwest Eye Banks; Tissue Banks International and other collaboratorsCompletedCorneal Disease | Fuch's Dystrophy | Pseudophakic Corneal EdemaUnited States
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...UnknownFuchs' Corneal Endothelial DystrophyUnited States
-
EmmecellRecruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownOther Endothelial Dystrophy
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
Clinical Trials on Tan Endoglide
-
University Health Network, TorontoUnknownEndothelial Cell Loss With Different Insertion DevicesCanada
-
University Health Network, TorontoUnknownEndothelial Cell Loss With Different Insertion DevicesCanada
-
Singapore Eye Research InstituteUK Network MedicalCompleted
-
Medical University of South CarolinaRecruiting
-
University of LuebeckCompleted
-
University of CincinnatiSpark Biomedical, Inc.Not yet recruitingOpioid Use Disorder | Posttraumatic Stress DisorderUnited States
-
Spark Biomedical, Inc.CompletedOpioid-use Disorder | Opioid WithdrawalUnited States
-
GlaxoSmithKlineCompletedCongestion, NasalUnited States
-
GlaxoSmithKlineCompletedCongestion, NasalUnited States
-
Dongfang Hospital Beijing University of Chinese...Chongqing Traditional Chinese Medicine Hospital; Changchun University of Chinese... and other collaboratorsCompletedCognitive ImpairmentChina